Condition (MeSH)
Exostoses, Multiple Hereditary
ClinicalTrials.gov lists 12 trials for Exostoses, Multiple Hereditary or a narrower condition beneath it. Clementia Pharmaceuticals Inc. has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
12 of the 12 trials are tagged with Exostoses, Multiple Hereditary itself; the rest are tagged with a narrower condition beneath it.
When did Exostoses, Multiple Hereditary trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 3 |
| 2024 | 1 |
| 2021 | 1 |
| 2018 | 2 |
| 2014 | 1 |
| 2013 | 1 |
| 2007 | 1 |
| 2004 | 1 |
| 1998 | 1 |
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 12 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Exostoses, Multiple Hereditary trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
| Not applicable | 1 |
| Observational | 10 |
How many Exostoses, Multiple Hereditary trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 3 |
| Completed | 6 |
| Suspended | 1 |
| Terminated | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Exostoses, Multiple Hereditary trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Clementia Pharmaceuticals Inc. | 1 |
Which drugs are being tested for Exostoses, Multiple Hereditary? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Palovarotene | 1 |
Which serious adverse events do Exostoses, Multiple Hereditary trials report? (5)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Blood Loss Anaemia | 1 | 1 |
| Pneumonia | 1 | 1 |
| Radius Fracture | 1 | 1 |
| Status Epilepticus | 1 | 1 |
| Ulna Fracture | 1 | 1 |
Which publications cover Exostoses, Multiple Hereditary? (17)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Palovarotene for patients with multiple hereditary exostosis: results of MO-Ped, a terminated, randomized, placebo-controlled, double-blind phase 2 trial. | Scientific reports | 2025 | Yes |
| Palovarotene Inhibits Osteochondroma Formation in a Mouse Model of Multiple Hereditary Exostoses. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research | 2018 | Yes |
| The impact of hereditary multiple exostoses on quality of life, satisfaction, global health status, and pain. | Archives of orthopaedic and trauma surgery | 2017 | Yes |
| Hereditary Multiple Exostoses: New Insights into Pathogenesis, Clinical Complications, and Potential Treatments. | Current osteoporosis reports | 2017 | Yes |
| Validation of a new multiple osteochondromas classification through Switching Neural Networks. | American journal of medical genetics. Part A | 2013 | Yes |
Showing 5 of 17 publications.
Prevalence (5)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Multiple osteochondromas | Point prevalence | 1-9 / 1 000 000 | United Kingdom | GB | Unspecified |
| Multiple osteochondromas | Point prevalence | 1-9 / 100 000 | United States | US | Unspecified |
| Multiple osteochondromas | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Unspecified |
| Multiple osteochondromas | Point prevalence | >1 / 1000 | Specific population | Not stated | Unspecified |
| Multiple osteochondromas | Point prevalence | 1-9 / 100 000 | Netherlands | Not stated | Unspecified |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: rare-disease identity and sub-conditions in mesh.